Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat NPDR.

Emory University School of Medicine, US, has commenced subject enrolment for BioCardia’s Phase III CardiAMP HF II trial.

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

Amgen's global Phase III DeLLphi-304 trial of Imdelltra has met its primary endpoint at a planned interim analysis for ...

Seismic Therapeutic has dosed the first healthy participant cohort in the randomised Phase I trial of bifunctional antibody S ...

J&J has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in treating plaque ...

MaaT Pharma has reported positive results from an interim safety analysis of its Phase IIb trial of MaaT033 in subjects ...

Breaking Science Session at the 2025 American Academy of Neurology (AAN) meeting, Remegen announced exciting results from a ...

After dropping the FNAIT therapy, Rallybio will prioritise another candidate that is being investigated in complement-driven ...

Oculis has concluded subject enrolment for the Phase III clinical trials of OCS-01 eye drops for diabetic macular oedema.

AI tools are faster at drafting clinical trial documents, but human writers remain indispensable for logical reasoning.

LifeMine Therapeutics has dosed the first subject in the Phase I trial of calcineurin inhibitor (CNi), LIFE-001.